A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
Context: Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic glucocorticoid doses to suppress adrenocorticotropic hormone (ACTH) and control androgen excess. Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce androgen excess independent of ACTH and thus allow for lower glucocorticoid dosing in CAH. 17-hydroxyprogesterone (17-OHP) and androstenedione are CAH biomarkers used to monitor androgen excess. Objective: Evaluate the efficacy and safety of nevanimibe in subjects with uncontrolled classic CAH. Design: This was a multicenter, single-blind, dose-titration study. CAH subjects with baseline 17-OHP ≥4× the upper limit of normal (ULN) received the lowest dose of nevanimibe for 2 weeks followed by a single-blind 2-week placebo washout. Nevanimibe was gradually titrated up if the primary outcome measure (17-OHP ≤2× ULN) was not met. A total of 5 nevanimibe dose levels were possible (125, 250, 500, 750, 1000 mg twice daily). Results: The study enrolled 10 adults: 9 completed the study, and 1 discontinued early due to a related serious adverse event. At baseline, the mean age was 30.3 ± 13.8 years, and the maintenance glucocorticoid dose, expressed as hydrocortisone equivalents, was 24.7 ± 10.4 mg/day. Two subjects met the primary endpoint, and 5 others experienced 17-OHP decreases ranging from 27% to 72% during nevanimibe treatment. The most common side effects were gastrointestinal (30%). There were no dose-related trends in adverse events. Conclusions: Nevanimibe decreased 17-OHP levels within 2 weeks of treatment. Larger studies of longer duration are needed to further evaluate its efficacy as add-on therapy for CAH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another oral, steroidogenic inhibitor studied in CAH is Nevanimibe124, a selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [124]
In the citing paper
“Although a drug effect was evident in 80% of patients during the treatment phase, only two patients (20%) met the primary end point of 17-OHP more than two times the upper limit of normal.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [124]
In the citing paper
“Gastrointestinal-related adverse effects were common (30%).”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [124]
In the citing paper
“A longer-duration study was terminated following an interim data review.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [124]
Citations
Cites
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Self-citationCongenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Self-citationHealth status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients
Arlt, W., Willis, D. S., Wild, S. H., Krone, N., Doherty, E. J., Hahner, S., Han, T. S., Carroll, P. V., Conway, G. S., Rees, D. A., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0917 · Cited by 506
Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia
Finkielstain, G. P., Kim, M. S., Sinaii, N., Nishitani, M., Van Ryzin, C., Hill, S. C., Reynolds, J. C., Hanna, R. M., & Merke, D. P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2102 · Cited by 313
Self-citationPW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Self-citationMammalian acyl-CoA:cholesterol acyltransferases
Buhman, K. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00144-x · Cited by 212
Falhammar, H., Frisén, L., Hirschberg, A. L., Norrby, C., Almqvist, C., Nordenskjöld, A., & Nordenström, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2093 · Cited by 204
Merke, D. P., Keil, M. F., Jones, J. V., Fields, J., Hill, S., & Cutler, G. B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.3.6462 · Cited by 190
Self-citationMallappa, A., Sinaii, N., Kumar, P., Whitaker, M. J., Daley, L.-A., Digweed, D., Eckland, D. J. A., Van Ryzin, C., Nieman, L. K., Arlt, W., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3809 · Cited by 167
Self-citationApproach to the patient: the adult with congenital adrenal hyperplasia
Auchus, R. J., & Arlt, W. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1440 · Cited by 121
Self-citationTreatment and health outcomes in adults with congenital adrenal hyperplasia
Han, T. S., Walker, B. R., Arlt, W., & Ross, R. J. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.239 · Cited by 102
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency
Auchus, R. J., Buschur, E. O., Chang, A. Y., Hammer, G. D., Ramm, C., Madrigal, D., Wang, G., Gonzalez, M., Xu, X. S., Smit, J. W., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1258 · Cited by 97
Self-citationNella, A. A., Mallappa, A., Perritt, A. F., Gounden, V., Kumar, P., Sinaii, N., Daley, L.-A., Ling, A., Liu, C.-Y., Soldin, S. J., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1916 · Cited by 91
Self-citationLaPensee, C. R., Mann, J. E., Rainey, W. E., Crudo, V., Hunt, S. W., & Hammer, G. D. (2016) · Endocrinology · doi:10.1210/en.2015-2052 · Cited by 86
Han, T. S., Krone, N., Willis, D. S., Conway, G. S., Hahner, S., Rees, D. A., Stimson, R. H., Walker, B. R., Arlt, W., Ross, R. J., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0128 · Cited by 79
Smith, D. C., Kroiß, M., Kebebew, E., Habra, M. A., Chugh, R. K., Schneider, B. J., Faßnacht, M., Jafarinasabian, P., Ijzerman, M. M., Lin, V. H., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00899-1 · Cited by 71
Self-citationGlucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia
Han, T. S., Stimson, R. H., Rees, D. A., Krone, N., Willis, D. S., Conway, G. S., Arlt, W., Walker, B. R., Ross, R. J., & (CaHASE), U. K. C. A. H. A. S. E. (2013) · Clinical Endocrinology · doi:10.1111/cen.12045 · Cited by 70
Subacute Toxicity of a Novel Inhibitor of Acyl-CoA: Cholesterol Acyltransferase in Beagle Dogs
Dominick, M. A., McGuire, E. J., Reindel, J. F., Bobrowski, W. F., Bocan, T. M., & Gough, A. W. (1993) · Fundamental and Applied Toxicology · doi:10.1006/faat.1993.1029 · Cited by 63
Turcu, A. F., Spencer-Segal, J. L., Farber, R. H., Luo, R., Grigoriadis, D. E., Ramm, C. A., Madrigal, D., Muth, T., O'Brien, C. F., & Auchus, R. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3574 · Cited by 61
Self-citationToxicologic Effects of a Novel Acyl-CoA: Cholesterol Acyltransferase Inhibitor in Cynomolgus Monkeys
Reindel, J. F., Dominick, M. A., Bocan, T. M. A., Gough, A. W., & McGuire, E. J. (1994) · Toxicologic Pathology · doi:10.1177/019262339402200505 · Cited by 38
Langlois, D. K., Fritz, M. C., Schall, W. D., Olivier, N. B., Smedley, R. C., Pearson, P. G., Bailie, M. B., & Hunt, S. W. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0251-5 · Cited by 24
Cited by
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationManagement challenges and therapeutic advances in congenital adrenal hyperplasia
Mallappa, A., & Merke, D. P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00655-w · Cited by 113
Self-citationAuchus, R. J., Sarafoglou, K., Fechner, P. Y., Vogiatzi, M. G., Imel, E. A., Davis, S. M., Giri, N., Sturgeon, J., Roberts, E., Chan, J. L., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab749 · Cited by 55
Self-citationAdrenally Directed Medical Therapies for Cushing Syndrome
Tritos, N. A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa778 · Cited by 54
Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia
Prete, A., Auchus, R. J., & Ross, R. J. (2022) · White Rose Research Online (University of Leeds, The University of Sheffield, University of York) · Cited by 46
Self-citation
Metadata
- Authors
- El-Maouche, D., Merke, D. P., Vogiatzi, M. G., Chang, A. Y., Turcu, A. F., Joyal, E. G., Lin, V. H., Weintraub, L., Plaunt, M. R., Mohideen, P., & Auchus, R. J.
- Affiliations
- Division of Endocrinology & Metabolism, George Washington University, Washington, DC
- National Institutes of Health (US)
- Division of Endocrinology and Diabetes, Children’s Hospital of Pennsylvania, Philadelphia, Pennsylvania
- Mayo Clinic (US)
- University of Michigan (US)
- Millendo Therapeutics (United States) (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2020-06-26
- Volume
- 105
- Issue
- 8
- Pages
- 2771-2778
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC7331874
- OpenAlex
- W3037125154
- Cited by
- 34
- References
- 22
- Citations by year
- 2026: 7 · 2025: 2 · 2024: 4 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 3
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, public-domain)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- congenital adrenal hyperplasia, 17-hydroxyprogesterone, hyperandrogenism, glucocorticoid dose reduction, dose titration, adverse events, adults
- MeSH terms
- Administration, Oral, Adolescent, Adrenal Cortex, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Adult, Androstenedione, Dose-Response Relationship, Drug, Drug Therapy, Combination, Glucocorticoids, Humans, Middle Aged, Urea, Biomarkers, Treatment Outcome, Cross-Over Studies, 17-alpha-Hydroxyprogesterone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.